DOCSLIB.ORG

A Adenoma, Follicular, 19 Adenosquamous Thyroid Carci

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Adenoma, Follicular, 19 Adenosquamous Thyroid Carci Index A c of well-differentiated thyroid Adenoma, follicular, 19 C cell hyperplasia, 83, 113, 120 carcinoma, 205-206 Adenosquamous thyroid carci- C cells, 116, 120-121 Childhood nontoxic goiter, 46 noma, 148-149 Calcitonin, 120-123 CHOP (cyclophosphamide, dox­ Adriamycin, 134, 158 Calcitonin gene-related peptide orubicin, vincristine and AOES classification schema, lO- (CORP),123 prednisone), 170,209 II Cancer, thyroid, see Thyroid car­ Chromogranin, 123 AMES scale, 11-12 cinoma CIS-platinum, 134 Amiodorone, 103 Capsular invasion, 20, 21 Clear nuclei, 2 Amyloid, 113, 118 Carcinoembryonic antigen Colloid nodule formation, 38-39 Anaplastic thyroid carcinoma (CEA),208-209 Core biopsy (CB), 19 (ATC), 60, 82-83, 142- Carcinoma Cowden's syndrome, 17 159 insular, 20, 148 Cyclophosphamide, doxorubicin, chemotherapy, 157-158,206- metastatic to thyroid gland, vincristine and prednisone 208 177-181 (CHOP), 170, 209 clinical picture, 143-144 recurrent, of childhood, 46 diagnosis, 154-156 small cell, 148 external radiation treatment, squamous cell, 147-148 D 195,200-202 thyroid, see Thyroid carcinoma Delphian node, 45 incidence, 143 CB (core biopsy), 19 Diiodotyrosine (DIT), 86-87 pathology, 144-150 CEA (carcinoembryonic antigen), Diploid cells, 9-10 pathophysiology, 150-154 208-209 DIT (diiodotyrosine), 86-87 radiation therapy, 157 Cervical adenopathy, 4-5 DNA ploidy, 9-10 surgery, 156-157 Cervical lymphadenopathy, 48 DOPA-decarboxylase, 123 survival data, 158-159 Cervical node metastases, 6 Doxorubicin, 134, 205-206 therapy, 156-158 CORP (calcitonin gene-related Dyshormonogenetic goiter, 46 Aneuploid cells, 9-10 peptide), 123 Antithyroid drugs, 103 Chemotherapy APUD-cell tumors, 118, 123, of advanced thyroid carci­ E 208 noma, 204-211 EOF (epithelial growth factor), Askanazy cell carcinoma, 16 of anaplastic thyroid carci- 150 ATC, see Anaplastic thyroid noma, 157-158,206-208 Endocrine-dependent tumors, carcinoma biological basis for, 204 102 Autoimmune thyroiditis, 47-48 clinical goals for, 204-205 EORTC (European Organization current recommendations, 210- for Research on Treatment 211 of Thyroid Cancer) index, B of medullary thyroid carci­ 10-12 Bilateral resection, 54 noma, 134,208-209 Epithelial growth factor (EOF), Biogenic amines, 117-119 principles of, 204-205 150 Bony metastases, 106 of thyroid lymphoma, 171, Epithelial tumor markers, Brain metastases, 58 209-210 149 215 216 INDEX European Organization for Re­ Hodgkin's disease, primary, of cytometry, 124-125 search on Treatment of thyroid gland, 174 demographics, 112 Thyroid Cancer (EORTC) Hormonal tumor markers, 149 detection of residual disease, index, 10-12 Hiirthle cell cancer, 77 132-133 Hiirthle cell carcinoma, 16 disease probability statistics, Hiirthle cell tumors, 26, 66 130-131 F Hypercalcitoninemia, 132 external radiation treatment, Fine needle aspiration (FNA), 19, Hyperparathyroidism, 42, 106 189,194,200 50-51, 155, 163-164 Hyperthyroxinemia, 108 familial, 83, 125-127 technique of, 67 Hypoparathyroidism, 54, 69-70, histopathology, 113, 116-118 FMD (moderately differentiated 80,106 molecular biology, 134-137 follicular carcinoma), 20- pathologic variants, 119-120 21 prognostic features, 124 FNA, see Fine needle aspiration I radiation therapy, 133-134 Focal hyperplasia, 38 Immunoenzymometry (lEMA), screening studies, 127-129 Follicular adenoma, 19 90 sporadic, 83 Follicular thyroid carcinoma, 16- Immunoradiometry (IRMA), 90 surgery for, 83-84, 131-132 29 Insular carcinoma, 20, 148 therapeutic modalities, 131- clear cell variant, 21, 23 Intermediate filaments, 150 134 clinical features, 17-19 Iodine, 100 Metastases epidemiology, 16-17 radioactive, see Radioactive io- bony, 106 external radiation treatment, dine brain, 58 185-188, 193 Iodine deficiency, 151 cervical node, 6 minimally invasive, 20 Iodine dyes, 103 distant, 105 moderately differentiated Iodine intake, 16-17 lung, 58, 105 (FMD), 20-21 Ipsilateral lobectomy, 54 neck node, 78, 82 oxyphilic cell type, 21, 23 IRMA (immunoradiometry), 90 to thyroid gland, 177-181 pathology, 19-23 Irradiation, neck, 46-47 Midline compartment recurrence, prognosis, 23-26 Isotopic scanning, 101 79-80 treatment, 23-29 Minimally invasive follicular car­ well-differentiated (FWD), 20- cinoma,20 21 J Monoiodotyrosine (MIT), 86-87 widely invasive, 20, 22 Jugular lymph nodes, 83-84 Multicentricity, 5-6, 69 Frozen section, 68 FWD (well-differentiated follicu­ lar carcinoma), 20-21 L N Large needle biopsy, 155 Near-total thyroidectomy, 75, Levothyroxine, 82 76 G Lithium, 103 Neck dissection Gallium 67 imaging, 163 Lobectomy, thyroid, 68-69 modified, 54 Gastrin-releasing peptide (GRP), ipsilateral, 54 technique of, 78-79 123-124 Lung metastases, 58, 105 Neck irradiation, 46-47 Gene mutation rate, 54 Lymph gland involvement, 39 Neck node metastases, 78, 82 Giant cell undifferentiated can­ Lymph nodes, jugular, 83-84 Needle biopsy, 19 cers, 60 Lymphadenopathy, cervical, 48 file, see Fine needle aspiration Giant cells, 145-147 Lymphocytic infiltration, 166 large, 155 Goiter, 16-17,36-37, 151 Lymphoma of thyroid gland, see Nerve growth factor, 134 childhood nontoxic, 46 Thyroid gland lymphoma Nodularity, thyroid, 45, 47 dyshormonogenetic, 46 Nontoxic goiter, 46 Granules, secretory, 116 Nuclear groove, 2-3 Graves' disease, 11 M Nuclear ploidy, 9-10 GRP (gastrin-releasing peptide), Mass spectrometry, 80 123-124 Medullary thyroid carcinoma, 38, 39,112-137 o associated endocrinopathy, Occult papillary carcinoma of H 129-130 thyroid, 5, 7-9 Hashimoto's thyroiditis, 48 calcitonin and, 120-123 Octreatide, 134 Hemiagenesis, thyroidal, 45-46 chemotherapy, 134,208-209 Orphan Annie Eyes, 2-3 Hemorrhage, postoperative, 80 clinical presentation, 112-113 Osteoporosis, 56 Histaminase, 123 cytology, 113, 114-115 Oxyphil cell carcinoma, 16 p Radiation treatment for thyroid papillary, see Papillary thyroid Papillae, 1-2 carcinoma, 182-203 carcinoma Papillary thyroid carcinoma, 1- Radioactive iodine (RaI), 25, 27- pediatric, see Pediatric entries 13 29,41,54-55 radiation-induced, 32-42 external radiation treatment, adverse effects of, 106-108 radioactive iodine treatment of, 184-188, 193 protocols for, 103-104 100-109 extrathyroidal spread of, 6 secondary effects of, 108 residual, 104-105 larger than 1.5 cm, 4-7 treatment of thyroid carci- significance of microscopic dis­ less than 1.5 cm, 8 noma, 100-109 ease, 66-67 mortality data, 4, 6-7 Recurrent disease, management staging, 144 multicentricity of, 5-6 of, 81-82 undifferentiated, see Undiffer­ nucle'lf DNA content in, 9-10 Roentgen ray therapy, 32 entiated thyroid carcinoma occult, 6, 7-9 well-differentiated, see Well­ pathology, 1-3 differentiated thyroid car­ predictive models, 10-12 S cinoma treatment, 12-13 Sarcomatous tumor markers, 149 Thyroid gland Parafollicular cells, see C cell en- Secretory granules and vacuoles, amount removed, 68-70 tries 116 carcinoma metastatic to, 177- Parathyroid disease, 130 Sialoadenitis. 106 181 Parathyroid glands, 73, 74 Small cell carcinoma, 148 lymphoma of, see Thyroid Pediatric thyroid carcinoma, 45- Spindle cells, 147 gland lymphoma 61 Spindle undifferentiated cancers, pediatric, 45-46 clinical presentation, 48-49 60 plasmacytoma of, 172-174 demographics, 46 Squamoid pattern, 148 primary Hodgkin's disease of, diagnostic approach, 49-51 Squamous cell carcinoma, 147- 174 general survey, 46-51 148 Thyroid gland lymphoma, 162- identification of risk factors, 174 46-48 chemotherapy, 171,209-210 management of, 50 T clinical features, 162-164 natural history and cause of T3 (triiodothyronine), 86, 102 differential diagnosis, 164-165 death,51 Tapazole, 103 factors influencing survival, prognosis, 56-59 Teratoma, 60 172 sites of recurrence of, 52 Tetraiodothyronine, see Thyrox- histopathology, 165-167 surgical findings, 51 ineentries pathology, 165-168 varieties of, 51-60 Tetraploid cells, 9-10 pathophysiology, 168-169 Pediatric thyroid gland, 45-46 TO, see Thyroglobulin radiotherapy, 169-171 Pentagastrin, 121-122 Thyrocalcitonin, 83 recommendations for treat- Perchlorate, 103 Thyroglobulin (TO), 56, 86-97 ment,I71-172 Pheochromocytoma, 125-126 classic, 86 surgery, 169 Plasmacytoma of thyroid gland, genetic abnormalities in forma- therapy, 169-171 172-174 tion of, 87-88 Thyroid hormonal treatment of Postoperative hemorrhage, 80 measurement, 89-97 papillary cancer, 12-13 Pregnancy, 106 physiology, 88-89 Thyroid hormone formation, 86- Primary Hodgkin's disease of structure and synthesis, 86 87 thyroid gland, 174 Thyroid carcinoma Thyroid lobectomy, see Lobec­ Propylthiouracil, 103 adenosquamous, 148-149 tomy, thyroid Psammoma bodies, 3, 39, 49 advanced, chemotherapy of, Thyroid neoplasia, 33 Pulse oximeter, 80 204-211 uncommon, 59-60 amount of thyroid removed in, Thyroid nodularity, 45, 47 68-70 surgical approach to, 67-68 R anaplastic, see Anaplastic thy- Thyroid stimulating antibody Radiation-induced thyroid carci- roid carcinoma (TSAb),17 noma, 32-42 classification, 65-66 Thyroid-stimulating hormone definition, 32-33 differentiated, 16 (TSH), 13, 17,27,55-56, diagnosis and treatment, 39-42 external radiation treatment 82, 101-102, 153-154 estimated risk of, 35, 36 for, 182-203 Thyroid storm, 108 incidence, 33-38 follicular, see Follicular thyroid Thyroid suppression therapy, 55- pathology, 38-39 carcinoma 56 radiation dose factors in, 34-38 medullary, see Medullary thy­ Thyroid teratoma, 60 Radiation threshold, 34 roid carcinoma Thyroid tissue, altered, 179 Thyroidal hemiagenesis, 45-46 TSAb (thyroid stimulating anti­ W Thyroidectomy, 26-28 body),17 Well-differentiated
Load more

Recommended publications
  • Basedow's Bonanza-Graves' Disease
    Journal of Liver Research, Disorders & Therapy Short Communication Open Access The prosperous goitre: basedow’s bonanza-graves’ disease Keywords: graves’ disease, auto-antibodies, thyroid gland, goiter, HLA CD40, CTLA-4, thyroglobulin, TSH receptor, PTPN 22, T cell Volume 4 Issue 3 - 2018 cytokines, toxic goitre, autoimmune hyperthyroidism, oncocytes Anubha Bajaj Abbreviations: TS Ab, thyroid stimulating antibody; TBII, Laboratory AB Diagnostics, India TSH binding inhibitor immunoglobulin; TSB Ab: thyroid stimulation blocking antibody; Anti TPO Ab, anti thyroid peroxidase antibody; Correspondence: Anubha Bajaj, Laboratory A.B. Diagnostics, Anti TG Ab, anti thyroglobulin antibody; TG, thyroglobulin; TSH R, A-1, Ring Road, Rajouri Garden, New Delhi 110027, India, Email [email protected] thyrotropin receptor; HLA, human leucocyte antigen; TRAb, TSH receptor autoantibodies Received: April 6, 2018 | Published: May 11, 2018 Introduction iodide symporter (a protein located in the baso-lateral membrane of An autoimmune disease constituting of hyperthyroidism due the thyrocytes) with an enhanced iodine uptake and a deficiency of to circulating auto-antibodies against thyrotropin (TSH receptor) TSH receptor which mobilizes protein C kinase pathway to control is delineated as Graves Disease.1 An upsurge in thyroid hormone cell proliferation. Pituitary secretion of TSH is restricted with synthesis, secretions and glandular enlargement is elucidated. Aberrant the antagonistic feedback mechanism of the accumulated thyroid glandular stimulation
    [Show full text]
  • Treatment of Radiation-Induced Nodular Goiters
    TREATMENT OF RADIATION-INDUCED NODULAR GOITERS ZsoltG. de Papp,RalphA. Pincusand LouisH. Hempelmann University of Rochester School of Medicine and Dentistry, Rochester, New York Retrospective and prospective epidemiological all patients presented to palpation as solitary or mul studies have shown that prior radiation exposure is tiple nodulesrangingin size from somethat were an important factor in the development of thyroid barely palpable to one massive nodular goiter meas cancer and multinodular goiter in adolescents and uring 6 X 8 X 2 cm. Prior to start of therapy, all young adults (1 ) . In retrospective studies of young patients were examined at least twice by the two persons with thyroid cancer, a history of antecedent senior authors to check on the accuracy and re radiation therapy to the neck or upper chest can producibility of the clinical findings. In each patient usually be elicited by specific questioning (2) . In with a palpably abnormal gland, the serum PB! and prospectivesurveysof selectedpopulationsof young 24-hr 131Juptake were determined, and a “scintiscan― adults with known radiation exposure, the incidence of the gland was carried out. In all but one patient, of neoplasticthyroid diseasecan be remarkably there was no evidence of hypothyroidism. high (1 ) . For example, in the 19 young Marshall In seven patients with nonfunctioning, fixed, stony, Islanders whose thyroid glands were heavily irradi hard or rapidly enlarging nodules, surgery was per ated during childhood by radioactive fission products formed. This was followed by suppressive therapy from a nuclear explosion in 1954, 15 or 78% de with L-thyroxin (0.2 mg daily) for 10 days; then, veloped nodular thyroid disease by 1967 (3) .
    [Show full text]
  • Thyroid Ultrasound
    Review Article Thyroid ultrasound Vikas Chaudhary, Shahina Bano1 Department of Radiodiagnosis, Employees’ State Insurance Corporation Model Hospital, Gurgaon, Haryana, 1Department of Radiodiagnosis, Lady Hardinge Medical College and Associated Smt. Sucheta Kriplani and Kalawati Hospitals, New Delhi, India ABSTRACT Thyroid ultrasonography has established itself as a popular and useful tool in the evaluation and management of thyroid disorders. Advanced ultrasound techniques in thyroid imaging have not only fascinated the radiologists but also attracted the surgeons and endocrinologists who are using these techniques in their daily clinical and operative practice. This review provides an overview of indications for ultrasound in various thyroid diseases, describes characteristic ultrasound findings in these diseases, and illustrates major diagnostic pitfalls of thyroid ultrasound. Key words: Color doppler, high resolution ultrasonography, thyroid, ultrasound, ultrasound elastography INTRODUCTION 1. To confirm presence of a thyroid nodule when physical examination is equivocal. High‑resolution ultrasonography (USG) is the most sensitive 2. To characterize a thyroid nodule(s), i.e. to measure the imaging modality available for examination of the thyroid dimensions accurately and to identify internal structure gland and associated abnormalities. Ultrasound scanning is and vascularization. non‑invasive, widely available, less expensive, and does not use 3. To differentiate between benign and malignant thyroid any ionizing radiation. Further, real time ultrasound imaging masses, based on their sonographic appearance. helps to guide diagnostic and therapeutic interventional 4. To differentiate between thyroid nodules and other procedures in cases of thyroid disease. The major limitation cervical masses like lymphadenopathy, thyroglossal cyst of ultrasound in thyroid imaging is that it cannot determine and cystic hygroma.
    [Show full text]
  • Thyroid Nodules Are Extremely Common in the General Population
    2. THE PATHOLOGY OF THYROID CANCER SYLVIA L. ASA Professor, Department of Laboratory Medicine & Pathobiology, University of Toronto; Pathologist-in-Chief, University Health Network and Toronto Medical Laboratories; Freeman Centre for Endocrine Oncology, Mount Sinai & Princess Margaret Hospitals; Toronto, Ontario Canada Thyroid nodules are extremely common in the general population; it has been esti- mated that about 20% of the population has a palpable thyroid nodule and approxi- mately 70% has a nodule that can be detected by ultrasound (1). The prevalence of thyroid nodules is greater in women than in men, and multiple nodules are more common than solitary nodules. The differential diagnosis of the thyroid nodule includes numerous entities, non-neoplastic and neoplastic, benign and malignant (2–5). The pathologist has an important role to play in their evaluation. The use of fine needle aspiration biopsy has significantly improved our ability to identify specific high-risk disorders and to facilitate their management in an expeditious and cost-effective manner. Patients who require surgery for further confirmation of the disease process rely upon the pathologist to correctly characterise their nodule and pathologists are actively involved in research to clarify the pathogenesis of thyroid disease. While some of these entities are readily diagnosed based on specific features seen in a routine slide stained with conventional dyes, the morphologic evaluation of many of these lesions is fraught with controversy and diagnostic criteria are highly variable from Pathologist to Pathologist (6). Nevertheless, histology remains the gold standard against which we measure outcomes of cytology, intraoperative consultations, molecular and other studies, and it represents the basis on which we determine patient management and the efficacy of various therapies.
    [Show full text]
  • Thyroid Nodules Update in Diagnosis and Management Shrikant Tamhane1* and Hossein Gharib2,3
    Tamhane and Gharib Clinical Diabetes and Endocrinology (2015) 1:11 DOI 10.1186/s40842-015-0011-7 REVIEW ARTICLE Open Access Thyroid nodules update in diagnosis and management Shrikant Tamhane1* and Hossein Gharib2,3 Abstract Thyroid nodules are very common. With widespread use of sensitive imaging in clinical practice, incidental thyroid nodules are being discovered with increasing frequency. Their clinical importance is primarily related to the need to exclude malignancy (4.0 to 6.5 percent of all thyroid nodules), assess for their functional status and any pressure symptoms caused by them. New Molecular tests are marketed for the assessment of thyroid nodules for the presence of cancer. The high prevalence of thyroid nodules requires evidence-based rational strategies for their differential diagnosis, risk stratification, treatment, and follow-up. This review addresses advances and controversies in thyroid nodule evaluation, including the new molecular tests, and their management considering the current guidelines and supporting evidence. Keywords: Thyroid, Thyroid Nodules, Molecular markers, Benign, Malignant, FNA, Management, Ultrasonography Introduction disorders, benign and malignant can cause thyroid nod- Thyroid nodule is a discrete lesion within the thyroid ules (Table 1) [1, 5]. gland that is radiologically distinct from the surrounding Fine needle aspiration (FNA) biopsy is the most accur- thyroid parenchyma. Thyroid nodules are common. ate method for evaluating thyroid nodules and helps to They are discovered as an accidental finding by a pa- identify patients who require surgical resection [6]. If a tient, or as an incidental finding during a routine phys- serum TSH is normal or elevated, and the nodule meets ical examination in 3 to 7 % [1] or by a radiologic criteria for sampling, the next step in the evaluation of a procedure: 67 % with ultrasonography (US) imaging, thyroid nodule is a FNA biopsy.
    [Show full text]
  • Heterogenous Morphologic Forms of Goiter in Autoimmune Thyroid Disease
    WJOES Heterogenous Morphologic Forms of Goiter in Autoimmune Thyroid Disease: An Insight based10.5005/jp-journals-10002-1140 on a Prospective Surgical Series ORIGINAL ARTICLE Heterogenous Morphologic Forms of Goiter in Autoimmune Thyroid Disease: An Insight based on a Prospective Surgical Series of 88 Cases PRK Bhargav ABSTRACT Usually, both GD and HT have diffuse goiter due to bilateral Two commonest forms of autoimmune thyroid disease (AITD) symmetrical involvement of thyroid gland by the disease are Graves’ disease (GD) and Hashimoto’s thyroiditis (HT) with process.7 But, in 20 to 30% of cases, they may be associated a diffuse goiter. The nature of goiter apart from clinical presenta- with nodules or assymetrical enlargement.8-11 The variability tion is crucial in the management of AITD. But, the goiter is not always diffuse, leading to diagnostic confusion. In this context, in proportion of nodularity depends upon clinical or sono- we conducted a prospective study on the goiter morphology in graphic methods of evaluation. In a classical case of AITD AITD. This is a prospective study conducted in Endocrine Surgery department of a teritiary care teaching hospital in South India (i.e. with usual clinical presentation, cardinal signs and over a period of 1 year. The cohort is a surgical series of 88 cases diffuse goiter), the standard diagnostic protocol with imaging of AITD (GD = 53; HT = 35). Morpho logy of all the ex vivo speci- and serology suffices, but appears to be insufficient in AITD mens were studied, documented and correlated with clinical and radiological forms of goiter. Sex ratio was M:F = 74:14.
    [Show full text]
  • Thyroid Nodules MARY JO WELKER, M.D., and DIANE ORLOV, M.S., C.N.P
    PRACTICAL THERAPEUTICS Thyroid Nodules MARY JO WELKER, M.D., and DIANE ORLOV, M.S., C.N.P. Ohio State University College of Medicine and Public Health, Columbus, Ohio Palpable thyroid nodules occur in 4 to 7 percent of the population, but nodules found incidentally on ultrasonography suggest a prevalence of 19 to 67 percent. The major- O A patient informa- ity of thyroid nodules are asymptomatic. Because about 5 percent of all palpable nod- tion handout on thy- roid nodules, written ules are found to be malignant, the main objective of evaluating thyroid nodules is to by the authors of this exclude malignancy. Laboratory evaluation, including a thyroid-stimulating hormone article, is provided on test, can help differentiate a thyrotoxic nodule from an euthyroid nodule. In euthyroid page 573. patients with a nodule, fine-needle aspiration should be performed, and radionuclide scanning should be reserved for patients with indeterminate cytology or thyrotoxico- sis. Insufficient specimens from fine-needle aspiration decrease when ultrasound guidance is used. Surgery is the primary treatment for malignant lesions, and the extent of surgery depends on the extent and type of disease. Ablation by postopera- tive radioactive iodine is done for high-risk patients—identified as those with metasta- tic or residual disease. While suppressive therapy with thyroxine is frequently used postoperatively for malignant lesions, its use for management of benign solitary thy- roid nodules remains controversial. (Am Fam Physician 2003;67:559-66,573-4. Copy- right© 2003 American Academy of Family Physicians.) Members of various thyroid nodule is a palpable jects 19 to 50 years of age had an incidental family practice depart- swelling in a thyroid gland with nodule on ultrasonography.
    [Show full text]
  • Anatomy, Physiology and Pathology of the Thyroid Gland Anatomy Thyroidthyroid Anatomyanatomy
    Thyroid Tarek Mahdy Ass Professor of Endocrine And Bariatric Surgery Mansoura Faculty Of Medicine Mansoura - Egypt TheThe ThyroidThyroid GlandGland NamedNamed afterafter thethe thyroidthyroid cartilagecartilage (Greek:(Greek: ShieldShield--shaped)shaped) TheThe ThyroidThyroid GlandGland VercelloniVercelloni 1711:1711: ““aa bagbag ofof wormsworms”” whosewhose eggseggs passpass intointo thethe esophagusesophagus forfor digestivedigestive purposespurposes ParryParry 1825:1825: ““aa vascularvascular shuntshunt”” toto cushioncushion thethe brainbrain fromfrom suddensudden increasesincreases inin bloodblood flowflow ThyroidThyroid EmbryologyEmbryology Medial portion of thyroid gland Arises frome the endodermal tissue of the base of tongue posteriorly, the foramen cecum - lack of migration results in a retrolingual mass Attached to tongue by the thyroglossal duct - lack of atrophy after thyroid descent results in midline cyst formation (thyroglossal duct cyst) Descent occurs about fifth week of fetal life - remnants may persist along track of descent Lateral lobes of thyroid gland Derived from a portion of ultimobranchial body, part of the fifth branchial pouch from which C cells are also derived (calcitonin secreting cells) Lingual Thyroid (failure of descent) Verification that lingual mass is thyroid by its ability to trap I123 Lingual thyroid Chin marker Significance: May be only thyroid tissue in body (~70% of time), removal resulting in hypothyroidism; treatment consists of TSH suppression to shrink size Anatomy, physiology and
    [Show full text]
  • NACB LMPG Thyroid Disease
    Volume 13/2002 The National Academy of Clinical Biochemistry Presents LABORATORY MEDICINE PRACTICE GUIDELINES LABORATORY SUPPORT FOR THE DIAGNOSIS OF THYROID DISEASE ARCHIVED NACB: Laboratory Support for the Diagnosis and Monitoring of Thyroid Disease Laurence M. Demers, Ph.D., F.A.C.B.and Carole A. Spencer Ph.D., F.A.C.B. LABORATORY MEDICINE PRACTICE GUIDELINES Laboratory Support for the Diagnosis and Monitoring of Thyroid Disease Table of Contents Section I. Foreword and Introduction Section 2. Pre-analytic factors Section 3. Thyroid Tests for the Laboratorian and Physician A. Total Thyroxine (TT4) and Total Triiodothyronine (TT3) methods B. Free Thyroxine (FT4) and Free Triiodothyronine (FT3) tests C. Thyrotropin/ Thyroid Stimulating Hormone (TSH) measurement D. Thyroid Autoantibodies: • Thyroid Peroxidase Antibodies (TPOAb) • Thyroglobulin Antibodies (TgAb) • Thyrotrophin Receptor Antibodies (TRAb) E. Thyroglobulin (Tg) Measurement F. Calcitonin (CT) and ret Proto-oncogene G. Urinary Iodide Measurement H. Thyroid Fine Needle Aspiration (FNA) and Cytology I. Screening for Congenital Hypothyroidism Section 4. The Importance of the Laboratory - Physician Interface Appendices and Glossary References Editors: Laurence M. Demers, Ph.D., F.A.C.B. Carole A. Spencer Ph.D., F.A.C.B. Guidelines Committee: The preparation of this revised monograph was achieved with the expert input of the editors, members of the guidelines committee, experts who submitted manuscripts for each section and many expert reviewers, who are listed in Appendix A. The material in this monograph represents the opinions of the editors and does not represent the official position of the National Academy of Clinical Biochemistry or any of the co-sponsoring organizations. The National Academy of Clinical Biochemistry is the official academy of the American Association of Clinical Chemistry.
    [Show full text]
  • Study of Pathological Variations of Solitary Thyroid Nodule by Abdullah Al Mamun, Zahedul Alam, Rojibul Haque & Dewan M Hasan National Institute of ENT, Bangladesh
    Global Journal of Medical Research: J Dentistry and Otolaryngology Volume 14 Issue 3 Version 1.0 Year 2014 Type: Double Blind Peer Reviewed International Research Journal Publisher: Global Journals Inc. (USA) Online ISSN: 2249-4618 & Print ISSN: 0975-5888 Study of Pathological Variations of Solitary Thyroid Nodule By Abdullah Al Mamun, Zahedul Alam, Rojibul Haque & Dewan M Hasan National Institute of ENT, Bangladesh Abstract- Objective: To find out the incidence of malignancy in patient with solitary thyroid nodule. Methods: This cross-sectional study was carried out with 100 solitary thyroid nodular patients who admitted in Otolaryngology & Head-Neck Surgery Department of Sir Salimullah Medical College Mitford Hospital (SSMCMH) & Bangabondhu Sheikh Mujib Medical Univercity (BSMMU), Dhaka, from July 2011 to December 2012,where all patients were admitted through out patient department. All patients were selected as per described criteria from the Department of Otolaryngology & Head-Neck Surgery, SSMCMH & BSMMU. Diagnosed the cases by detail history, clinical examination,investigations,analysed data presented by various tables, figures. Results: In this study mean age of the patients of solitary thyroid nodule was 35.6±13.54 years and the highest frequency (38%) was within 21-30 years of age with female predominance (78%). Thyroid swelling was the common presentation in all9100%) cases, some patients also presented with other symptoms like cervical lymphadenopathy 13(13%) cases, dysphagia 1(1%), dyspnoea 1(1%), hoarseness of voice 1(1%) case & no bone metastetic found. Keywords: solitary thyroid nodule, papillary carcinoma, follicular carcinoma, medulary carcinoma. GJMR-J Classification: NLMC Code: WK 200, WF 490 StudyofPathologicalVariationsofSolitaryThyroidNodule Strictly as per the compliance and regulations of: © 2014.
    [Show full text]
  • 9| Thyroid Disorders 10
    433 Medicine Team Thyroid disorders 10|Thyroid Disorders 9| Thyroid disorders 1 | P a g e 433 Medicine Team Thyroid disorders Objectives: 1. Describe the anatomy and physiology related to thyroid gland 2. Know the Hypothyroidism: presentation, diagnosis and management 3.Define the Goiter and thyroid nodules 2 | P a g e 433 Medicine Team Thyroid disorders Thyroid gland Thyroid gland is made up of follicles and has 2 lobes and connected by the isthmus • more volume in men, increase with age and bodyweight and decrease with iodine intake • Located in front of larynx 99.9 % of T4 and T3 are bound to protein in the blood: TBG, albumin, Thyroid hormones: lipoprotein Follicular cells of the thyroid is the main site of hormones synthesis • Mainly T4 and small amount of T3 • T4 and T3 synthesis and secretion is regulated by pituitary TSH. • TSH is inhibited by T4 and T3, stimulated by TRH Thyroid hormone action: Thyroid hormones In children: delayed act on the bone In brain: cognitive growth and and bone impairment epiphyseal growth development Regulate metabolic Act on cardiac rate and little muscle: tachy and change in bradycardia bodyweight Goiter: Chronic enlargement of thyroid gland not due to neoplasm What causes goiter: Goiters can occur when the thyroid gland produces either too much thyroid hormone (hyperthyroidism) Assess thyroid function by : not enough (hypothyroidism) Free T4, FT3 Normal production (nontoxic multinodular goiter) TSH Sporadic: Diet (cabbage, Caulifower) Ultrasound neck 3 | P a g e 433 Medicine Team Thyroid disorders HYPOTHYROIDISM: Etiology Failure of the thyroid to produce sufficient thyroid Hormone.
    [Show full text]
  • Goitre – Causes, Investigation and Management
    Thyroid Goitre Causes, investigation and management Kiernan Hughes Creswell Eastman Background Goitre refers to an enlarged thyroid gland. Causes of goitre Goitre refers to an enlarged thyroid. Common causes of goitre include autoimmune disease, the formation of one or more include autoimmune disease, thyroid nodules and iodine thyroid nodules and iodine deficiency (Table 1). Goitre deficiency. occurs when there is reduced thyroid hormone synthesis Objective secondary to biosynthetic defects and/or iodine deficiency, This article outlines the causes, investigation and leading to increased thyroid stimulating hormone (TSH). management of goitre in the Australian general practice This stimulates thyroid growth as a compensatory setting. mechanism to overcome the decreased hormone synthesis. Elevated TSH is also thought to contribute to an enlarged Discussion Patients with goitre may be asymptomatic, or may present thyroid in the goitrous form of Hashimoto thyroiditis, in with compressive symptoms such as cough or dysphagia. combination with fibrosis secondary to the autoimmune Goitre may also present with symptoms due to associated process in this condition. In Graves disease, the goitre hypothyroidism or hyperthyroidism. Thyroid stimulating results mainly from stimulation by the TSH receptor hormone is the appropriate first test for all patients with goitre; antibody (Figure 1). if this hormone is low a radionuclide scan is helpful. Thyroid ultrasound has become an extension of physical examination When diffuse enlargement of the thyroid occurs in the absence of and should be performed in all patients with goitre. Ultrasound nodules and hyperthyroidism, it is referred to as a diffuse nontoxic can determine what nodules should be biopsied. Treatment goitre. This is sometimes called ‘simple goitre’ because of the options for goitre depend on the cause and the clinical absence of nodules, or ‘colloid goitre’ because of the presence of picture and may include observation, iodine supplementation, uniform follicles that are filled with colloid.
    [Show full text]